Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Feedback inks collaboration deal with Vertex In Healthcare

(Sharecast News) - Clinical infrastructure specialist Feedback announced a collaboration agreement with Vertex In Healthcare, a clinical IT firm with a presence in the UK, the UAE, and South Africa, on Wednesday. The AIM-traded firm said the strategic partnership aimed to combine key technologies and resell each other's products to drive commercial opportunities across multiple markets.

It said the agreement would see Feedback integrate the MedDream viewer into its Bleepa platform, which would allow Bleepa to be marketed directly to radiologists for primary diagnostic reporting, enhancing Feedback's teleradiology offering and expanding its market reach to new territories, particularly the US.

By embedding a viewer with regulatory approval in various international markets, the combined Bleepa-MedDream product would reportedly meet the necessary requirements for direct sales.

While Feedback's primary international focus remained on the growing market opportunity in India, the collaboration opened potential expansion into key markets such as the US and the Middle East.

The collaboration also positioned both Feedback and Vertex to resell each other's products in multiple regions, leveraging each other's established footprints to facilitate rapid and cost-effective market expansion.

Bleepa's value and product differentiation were expected to enhance Vertex's existing solutions, helping grow market share across various customer segments.

Additionally, Vertex would licence the database capabilities of Feedback's legacy Cadran PACS system, now integrated with the MedDream Viewer, to develop a PACS proposition for markets including South Africa and the UK.

"Vertex is a great partner for Feedback - like us it is commercially minded, ambitious and on a clear mission to improve healthcare," said chief executive officer Dr Tom Oakley.

"Our products naturally fit together and create a compelling value proposition to customers, especially those who are increasingly looking for the most streamlined and cost-effective way of procuring the solutions that they need.

"Incorporating the MedDream viewer into Bleepa opens up new opportunities for us, both domestically to radiologists and internationally, allowing us to expand more rapidly if we see opportunities overseas, avoiding some of the difficulties that we had in registering Bleepa as a medical device directly in India."

At 1005 BST, shares in Feedback were up 3.82% at 68p.

Reporting by Josh White for Sharecast.com.

Share this article

Related Sharecast Articles

Apollo to buy IGT Gaming and Everi in $6.3bn deal
(Sharecast News) - Apollo Global Management has agreed to buy International Game Technology's gaming and digital business - IGT Gaming - and gambling machines firm Everi Holdings in a $6.3bn cash deal.
3M comfortably beats expectations for Q2 revenue, earnings
(Sharecast News) - American industrial conglomerate 3M announced a strong set of second-quarter results on Friday, comfortably beating market expectations as it narrowed its guidance for the full-year towards the top end of its previous expectations.
Law Debenture delivers 'solid' overall first-half performance
(Sharecast News) - Law Debenture Corporation reported a robust first-half performance in both its investment and independent professional services (IPS) business on Friday.
GCP Infrastructure reports slight decrease in NAV per share
(Sharecast News) - GCP Infrastructure Investments said in an update on Friday that its unaudited net asset value per share was 107.58p as at 30 June, a slight decrease from 107.62p at the end of March.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.